Press Releases
Date picker
Category
Results per page
Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
First quarter in briefJanuary – MarchFinancial summary for the first quarter and the period January - March 2022· Net sales amounted to SEK 0 million (SEK 0.0 million).· R&D costs…
Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), org.nr. 556806-8851
The year in briefOctober – DecemberFinancial summary for the fourth quarterNet sales amounted to SEK 0 million (0,0 million).R&D costs amounted to SEK 12,9 million (11,2 million).Operating profit for the…
Kancera appoints Peter Selin as Executive Vice President Corporate Development
Regulatory
Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of…
Kancera’s drug candidate KAND145 effectively reduces tumor size in a preclinical model of ovarian cancer
This is a translation of press release in Swedish (2021-11-22). Kancera AB (Nasdaq First North Premier Growth Market: KAN) today presents preclinical results that show that KAND145 effectively reduces tumor…
Kancera reports top-line data from the phase IIa study with KAND567 in COVID-19 patients
This is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with…
Interim report for third quarter 2021,1 January – 30 September 2021 Kancera AB (publ.), org.nr. 556806-8851
The year in brief Juli – SeptemberFinancial summary of the third quarterNet sales amounted to SEK 0 million (0,05 million).R&D costs amounted to SEK 10,9 million (8,8 million).Operating profit for…
Interim report for second quarter 2021. 1 January – 30 June 2021 Kancera AB (publ.)
Second quarter in brief as well as the period 1 January to 30 June 2021Net sales for the period (January to June) amounted to SEK 0 million (SEK 0 million), of…
Kancera has completed patient recruitment for the COVID-19 study with KAND567
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent…
Kancera announces that an application for a clinical phase IIa study with KAND567 after heart attack has been submitted to the UK Medicines Agency (MHRA)
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567…
Interim report for first quarter 2021, 1 January – 31 March 2021
Regulatory
First quarter in briefNet sales for the period (January to March) amounted to SEK 0 million (SEK 0 million).R&D costs for the period amounted to SEK 8,2 million (SEK 9,7…